These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28412971)

  • 41. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
    Brown SR; Hall A; Buckley HL; Flanagan L; Gonzalez de Castro D; Farnell K; Moss L; Gregory R; Newbold K; Du Y; Flux G; Wadsley J
    BMC Cancer; 2019 Jun; 19(1):582. PubMed ID: 31200667
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
    Wang E; Karedan T; Perez CA
    Anticancer Drugs; 2015 Aug; 26(7):689-97. PubMed ID: 25974026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
    Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
    N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lenvatinib: first global approval.
    Scott LJ
    Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prolonged duration of response in lenvatinib responders with thyroid cancer.
    Gianoukakis AG; Dutcus CE; Batty N; Guo M; Baig M
    Endocr Relat Cancer; 2018 Jun; 25(6):699-704. PubMed ID: 29752332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
    Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
    Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?
    Lorusso L; Newbold K
    Future Oncol; 2015; 11(12):1719-27. PubMed ID: 26075440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.
    Verburg FA; Amthauer H; Binse I; Brink I; Buck A; Darr A; Dierks C; Koch C; König U; Kreissl MC; Luster M; Reuter C; Scheidhauer K; Willenberg HS; Zielke A; Schott M
    Horm Metab Res; 2021 Mar; 53(3):149-160. PubMed ID: 33652491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
    Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
    BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
    Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer.
    Suzuki C; Kiyota N; Imamura Y; Goto H; Suto H; Chayahara N; Toyoda M; Ito Y; Miya A; Miyauchi A; Otsuki N; Nibu KI; Minami H
    Head Neck; 2019 Sep; 41(9):3023-3032. PubMed ID: 31013380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
    Herranz UA
    Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients.
    Fukuda N; Toda K; Udagawa S; Ohmoto A; Oki R; Suto H; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Endocrine; 2022 Apr; 76(1):70-77. PubMed ID: 35088293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lenvatinib in differentiated thyroid carcinoma: the Italian experience.
    Piovesan A
    Future Oncol; 2019 Aug; 15(24s):1-2. PubMed ID: 31385528
    [No Abstract]   [Full Text] [Related]  

  • 58. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lenvatinib improves survival in refractory thyroid cancer.
    Mayor S
    Lancet Oncol; 2015 Mar; 16(3):e110. PubMed ID: 25683848
    [No Abstract]   [Full Text] [Related]  

  • 60. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
    Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
    Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.